EU drug watchdog approves AstraZeneca COVID-19 prevention jab
FILE PHOTO: A general view is pictured of the offices of British-Swedish multinational pharmaceutical and biopharmaceutical company AstraZeneca PLC in Macclesfield, Cheshire on July 21, 2020. (Photo by Paul ELLIS / AFP)
The Hague, Netherlands — The EU’s drug watchdog on Thursday recommended for approval AstraZeneca’s COVID-19 prevention cocktail, which can be used for patients with immune system problems or severe reactions to other coronavirus vaccines.
The European Medicines Agency’s human medicines committee “has recommended granting a marketing authorization for Evusheld, developed by AstraZeneca for the prevention of COVID-19 in adults and adolescents from 12 years of age,” the Amsterdam-based EMA said in a statement.
Evusheld consists of two monoclonal antibodies tixagevimab and cilgavimab – proteins designed to attack the spike protein of the SARS-CoV-2 virus which causes COVID-19 – at two different sites, the EMA said.
It said data from a test on 5,000 people who were given two jabs, showed it reduced the risk of COVID-19 infection by 77 percent and protection lasted for at least six months.
The study was done on adults who had never had COVID-19 and had never received a vaccine or other preventative treatment, the EMA said.
Article continues after this advertisement“The safety profile of Evusheld was favorable and side effects were generally mild, with a small number of people reporting reactions at the injection site or hypersensitivity,” the medicines watchdog added.
Article continues after this advertisementBut the study was done before the emergence of the infectious Omicron strain of the virus and “laboratory studies show that the Omicron BA.1 variant may be less sensitive to tixagevimab and cilgavimab than the Omicron BA.2 variant,” the watchdog said.
The EMA’s recommendation will now be forwarded to the European Commission for final approval before distribution to the 27-member bloc.
Evusheld received the US-based FDA’s emergency authorization in December.
RELATED STORY
France approves antibody therapy for high-risk COVID-19 cases
For more news about the novel coronavirus click here.
What you need to know about Coronavirus.
For more information on COVID-19, call the DOH Hotline: (02) 86517800 local 1149/1150.
The Inquirer Foundation supports our healthcare frontliners and is still accepting cash donations to be deposited at Banco de Oro (BDO) current account #007960018860 or donate through PayMaya using this link.
